Therapy-related MDS dissected based on primary disease and treatment-a nationwide perspective

Area of Science:

• Hematology
• Oncology
• Epidemiology

Background:

• Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
• Therapy-related MDS (t-MDS) arises after exposure to chemotherapy or radiation therapy.
• Characterizing t-MDS subgroups is crucial for understanding prognosis and treatment implications.

Purpose of the Study:

• To characterize and compare subgroups of therapy-related Myelodysplastic syndromes (t-MDS).
• To define the prognostic implications of previous treatment type and primary disease in t-MDS.
• To investigate the prevalence of antecedent malignancies in MDS patients compared to the general population.

Main Methods:

• Population-based study utilizing the Swedish MDS register (2009-2017, n=2705).
• Combined MDS patient data with national health registers.
• Matched population controls were used to assess antecedent malignancy prevalence.

Main Results:

• t-MDS demonstrated significantly shorter median survival compared to de novo MDS (15.8 vs 31.1 months).
• Patients treated with chemotherapy showed a higher risk profile than those treated with radiation only.
• MDS patients had a 6-fold increased prevalence of prior hematological malignancy versus controls.

Conclusions:

• This nationwide study confirms poorer survival for t-MDS patients.
• Previous chemotherapy is associated with a worse prognosis in t-MDS.
• Prior hematological malignancy in t-MDS patients portends a dismal outcome.